Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 2, 2006, Pages 171-177

  Bozzetti, Cecilia ^a,e   Musolino, Antonino ^a   Camisa, Roberta ^a   Bisagni, Giancarlo ^c   Flora, Marcella ^c   Bassano, Cristina ^c   Martella, Eugenia ^b   Lagrasta, Costanza ^b   Nizzoli, Rita ^a   Personeni, Nicola ^d   Leonardi, Francesco ^a   Cocconi, Giorgio ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d JULES BORDET INSTITUTE   (Belgium)

^e Azienda Ospedaliera   (Italy)

Author keywords

Anthracyclines; Breast cancer; HER 2 neu; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; ANTHRACYCLINE; TUMOR MARKER;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PREDICTION; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; DOSE RESPONSE; GENE AMPLIFICATION; GENETICS; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645779551     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000204405.96572.f9     Document Type: Review

References (44)

1. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974-976.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
4. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049-1056.
6. Miles DW, Harris WH, Gillett CE, et al. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer. 1999;84:354-359.
7. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER-2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19:329-335.
8. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
9. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.
10. Pritchard K, O'Malley F, Andrulis I, et al. Prognostic and predictive value of HER-2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA. 5). Proc Am Soc Clin Oncol. 2002;21:42A
11. Paik S, Bryant J, Tan-Chiu E, et al. HER-2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991-1998.
12. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107-1116.
13. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992;89:5321-5325.
14. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
15. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
16. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol. 2002;13:1398-1403.
17. Bozzetti C, Personeni N, Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (Cancer Cytopathlogy). 2003;99:310-315.
18. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205-211.
19. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
20. Freeman DH. Applied Categorical Data Analysis. New York: Marcel Dekker, 1987.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1996;50:163-170.
23. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
24. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity are determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemina Group B. J Natl Cancer Inst. 1998;90:1205-1211.
25. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ Hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
26. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
27. Ravdin PM, Green S, Albain KS, et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone. Proc Am Soc Clin Oncol. 1998;17:97A.
28. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-1259.
29. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2, and GSTπ. Br J Cancer. 1996;74:1458-1465.
30. Vargas-Roig LM, Gago FE, Tello O, et al. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer. 1999;84:129-134.
31. Vincent-Salomon A, Carton M, Freneaux P, et al. ErbB-2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer. 2000;36:586-591.
32. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003;97:1758-1765.
33. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003;288:406-412.
34. Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends oh HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res. 2001;7:1577-1581.
35. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
36. Amat S, Penault-Llorca F, Cure H, et al. Scarf-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002;20:791-796.
37. Aas T, Geisler S, Eide GE, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2003;39:438-446.
38. Daidone MG, Veneroni S, Benini E, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer. 1999;84:580-586.
39. Remvikos Y, Jouve M, Beuzeboc P, et al. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer. 1993;29:1843-1848.
40. Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer. 1999;35:574-579.
41. Vincent-Salomon A, Rousseau A, Jouve M, et al. Breast Cancer Study Group: proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer. 2004;40:1502-1508.
42. Campiglio M, Somenzi G, Olgiati C, et al. Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer. 2003;105:568-573.
43. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
44. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.